WALDENSTROM MACROGLOBULINEMIA (WM)
Clinical trials for WALDENSTROM MACROGLOBULINEMIA (WM) explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA (WM) trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA (WM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA (WM)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …
Matched conditions: WALDENSTROM MACROGLOBULINEMIA (WM)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC